Neurogene

Neurogene Goodwill

Goodwill of Neurogene (NGNE) as of Oct 18, 2026.

Goodwill

-USD

Last updated:

Goodwill of Neurogene is 2026 - USD. Goodwill of Neurogene was 2025 - USD. It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neurogene Stock analysis

What does Neurogene do? Neurogene Inc, headquartered in New York City, operates in the Health Care sector within the Biotechnology industry. The company, listed on March 7, 2014, focuses on developing genetic medicines for rare neurological diseases. Its proprietary EXACT platform enables precise transgene regulation for therapies like NGN-401, an AAV9-based treatment for Rett syndrome, and NGN-101 for CLN5 Batten disease, aiming to overcome limitations of conventional gene therapy. Neurogene is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neurogene stock

On Eulerpool you can find the complete historical development of Goodwill Neurogene since 2006 – with annual values, charts, and detailed analysis.

Goodwill is the premium paid above fair market value in an acquisition. It represents intangible value such as brand recognition, customer relationships, and intellectual property.

Goodwill's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Goodwill's Neurogene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Neurogene

All Key Metrics — Neurogene